NazlinR - Transnasal Systemic Delivery of Insulin

  • John P. Longenecker
Part of the NATO ASI Series book series (NSSA, volume 125)

Abstract

I recently had a discussion with a scientist from a major “Eastern Establishment” pharmaceutical company in the U.S. The topic of our discussion was the success of this young upstart biotechnology industry. Although we were in agreement that biotechnology allows for a more rational approach to design of therapeutic agents, he argued that, “you cannot make it in the pharmaceutical industry simply on injectable hormones”. Whether or not the economic argument is valid, it is clear that widespread, patient-controlled use of therapeutic proteins and peptides demands an alternative to parenteral administration. The most likely route of administration for this relatively new and rapidly expanding class of therapeutic agents is via the nasal cavity. The highly vascularized mucosal surfaces of the nasal passages, the ease of administration, potential advantages of no first pass metabolism and the rapid kinetics of absorption make the nasal route an ideal alternative to parenteral administration. Transnasal systemic drug delivery has become a popular topic (Parr, 1983; Su, 1986) and was the subject of a recently published Symposium held at Rutgers University in New Jersey (Chien, 1985). The message from this meeting was that nasal drug delivery is indeed a viable alternative with significant therapeutic and kinetic advantages, especially for hormones. However, problems of bioavailability, reproducibility of plasma levels and effect on nasal pathology, i.e., local toxicity, remain to be solved.

Keywords

Bile Salt Insulin Dose Cholic Acid Therapeutic Protein Critical Micellar Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. Blundell, T.L., Cutfield, J.F., Cutfield, S.M., Dodson, E.J.; Dodson, G.G.; Hodgkin, D.C. and Mercola, D.A., 1972, Three dimensional atomic structure of insulin and its relationship to activity, Diabetes, 21: 492.PubMedGoogle Scholar
  2. Carey, M.C. and Small, D.M.; 1971, Micellar properties of sodium fusidate, a steroid antibiotic structurally resembling the bile salts, J. Lipid Res., 12: 604.PubMedGoogle Scholar
  3. Carey, M.C. and Small, D.M.; 1973 Solution properties of taurine and glycine conjugates of fusidic acid and its derivatives, Biochim et Biophys. Acta 305:51.Google Scholar
  4. Chien, Y.W., 1985 “Transnasal Systemic Medications: Fundamentals, Developmental Concepts and Biomedical Assessments” Elsevier-Amsterdam.Google Scholar
  5. Collens, W.S. and Goldzieher, 1932, Absorption of insulin by nasal mucous membrane, Proc. Soc. Exp. Bio. Med., 29: 756.Google Scholar
  6. Galloway, J.A.; Spradlin, C.T.; Nelson, R.L.; Wentworth, S.M.; Davidson, J.A. and Swarner, J.L. 1981, Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care, 3: 366.CrossRefGoogle Scholar
  7. Gansslen, M. 1925. Ueber inhalation van insulin Klin Schnschr 4:71.CrossRefGoogle Scholar
  8. Gordon, G.S.; Moses, A.C.; Silver, R.D.; Flier, J.S. and Carey, M.C. 1985, Nasal absorption of insulin: enhancement by hydrophobic bile salts, Proc. Natl. Acad. Sci. USA, 82: 7419.PubMedCrossRefGoogle Scholar
  9. Hankiss, J. and Hadhazy, C.S., 1958, Resorption von insulin and asthmolysin von der nasenschleimhaut, Acta. Med. Acad. Sci-Hung., 12: 107.PubMedGoogle Scholar
  10. Heubner, W.; de Jough, S.E.; and Laquer, E., 1924, Ueber inhalation von insulin, Klin Schnshr., 3: 2342.CrossRefGoogle Scholar
  11. Hirai, S.; Ikenaga, T. and Matsuzawa, T., 1978, Nasal Absorption of insulin in dogs, Diabetes, 27: 296.CrossRefGoogle Scholar
  12. Hirai, S.; Yashiki, T.; and Mima, H., 1981, Mechanisms for the enhancement of the nasal absorption of insulin by surfactants, Int. J. Pharm., 9: 173.CrossRefGoogle Scholar
  13. Jeffery, P.D., Milthorpe, B.K. and Nichol, L.W., 1976, Polymerization pattern of insulin at ph 7.0, Biochemistry, 15: 4460.Google Scholar
  14. Kimura, T.; Imamura, H.; Hasegawa, K.; and Yoshida, A., 1982 Mechanisims of toxicities of some detergents added to a diet and of the ameliorating effect of dietary fiber in the rat. J. Nut. Sci Vitaminol, 28:483.CrossRefGoogle Scholar
  15. Major, R.H., 1936, The intranasal application of insulin, experimental and clinical experiences, Am. J.M. Sci, 192: 257.CrossRefGoogle Scholar
  16. Martin, G.P., and Marriott, C, 1981, Membrane damage by bile salts: the protective function of phospholipids, J. Pharm. Pharmacol, 31: 754.CrossRefGoogle Scholar
  17. Moses, A.C.; Gordon, G.S.; Carey, M.C. and Flier, J.S., 1983, Insulin administered intranasally as an insulin-bile salt aerosol: effectiveness and reproducibility in normal and diabetic subjects, Diabetes, 32: 1040.PubMedCrossRefGoogle Scholar
  18. O’Leary, J.F.; Borner, J.w., Runge, W.J. Dehner, L.P. and Goodale, R.L., 1984, Hyperplasia of pancreatic duct epithelium produced by exposure to sodium deoxycholate, Am. J. Surg., 147: 72.PubMedCrossRefGoogle Scholar
  19. Parr, G.D., 1983, Nasal delivery of drugs, Pharm. Int. Aug:202.Google Scholar
  20. Pontiroli, A.E.; Alberetto, M.;.Secchi, A.S.; Dossi, G.; Bosi, I. and Pozza, G. 1982, Insulin given intranasally induces hypoglycemia in normal and diabetic subjects, Brit, Med. J., 284: 303.CrossRefGoogle Scholar
  21. Salzman, R.; Manson, J.E., Griffing, G.T.; Kimmerle, R.; Ruderman, N.; McCall, A.; Stoltz, E.I.; Mullin, C.; Small D.; Armstrong, J. and Melby, J.C., 1985, Intranasal aerosolized insulin: mixed meal studies and long-term use in type I diabetes N. Engl. J. Med., 312: 1078.PubMedCrossRefGoogle Scholar
  22. Scholmerich, J.; Becher, M.S.; Schmidt, K.; Schubert, R.; Kremer, B.; Feldhaus, S. and Gerok, W., 1984, Influence of hydroxylation and conjugation of bile salts on their membrane damaging properties — studies on isolated hepatoyates and lipid membrane vesicles, Hepatology, 4: 661.PubMedCrossRefGoogle Scholar
  23. Schubert, R.; Jaroni, H.; Schoelmerich, J. and Schmidt, K.H., 1983, Studies on the mechanism of bile salt-induced liposomal membrane damage, Digestion, 28: 181.PubMedCrossRefGoogle Scholar
  24. Su, K.S.E.; 1986, Intranasal delivery of peptides and proteins, Pharm. Int., 7: 8.Google Scholar
  25. Whitmore, D.A., Bookes, L.G. and Wheeler, K.P. 1979, Relative effects of different surfactants on intestinal absorption and the release of proteins and phospholipids from the tissue, J. Pharm. Pharmacol, 31: 277.PubMedCrossRefGoogle Scholar
  26. Woodyatt, R.T., 1922, The clinical use of insulin, J. Metab. Res., 2: 793.Google Scholar

Copyright information

© Springer Science+Business Media New York 1986

Authors and Affiliations

  • John P. Longenecker
    • 1
  1. 1.California Biotechnology, Inc.Mountain ViewUSA

Personalised recommendations